제약, 바이오테크놀러지 및 진단 분야의 코프로모션 및 코마케팅 제휴 계약과 합의
Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2014-2021
상품코드 : 239653
리서치사 : Current Partnering, a division of Wildwood Ventures Limited
발행일 : 2021년 04월
페이지 정보 : 영문 300+ Pages
US $ 3,495 ₩ 3,959,000
PDF (Single User License)
US $ 5,245 ₩ 5,941,000
PDF (Multi User License - 2 to 5 Users)
US $ 10,495 ₩ 11,888,000
PDF (Single Site License - 6+ Users)
US $ 17,495 ₩ 19,818,000
PDF (Global License)


한글목차

세계 주요 헬스케어 기업의 코프로모션(Co-promotion) 및 코마케팅(Co-marketing) 제휴에 대해 조사하고, 코프로모션 및 코마케팅 거래 동향, 합의 구조, 계약 서류, 계약액별 주요 거래 및 가장 활발한 중개업자 등의 분석을 전해드립니다.

개요

제1장 서론

제2장 코프로모션 및 코마케팅 거래 형성 동향

제3장 코프로모션 거래 구조 개요

제4장 코마케팅 거래 구조 개요

제5장 주요 코프로모션 거래

제6장 주요 코마케팅 거래

제7장 대형 제약 기업의 코프로모션 및 코마케팅 거래

제8장 코프로모션 합의 디렉토리

제9장 코마케팅 합의 디렉토리

부록

도표

KSM 12.05.22

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문 목차

영문목차

The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies.

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2014 to 2021.

For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.

Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.

Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a review of the top 25 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2014.

In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides the reader with the following key benefits:

Report scope

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 includes:

In Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021, the available contracts are listed by:

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive access to records for over 350 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:

Benefits

Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2014-2021 provides the reader with the following key benefits:

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-promotion and co-marketing dealmaking

Chapter 3 - Overview of co-promotion deal structure

Chapter 4 - Overview of co-marketing deal structure

Chapter 5 - Leading co-promotion and co-marketing deals

Chapter 6 - Top 25 most active co-promotion and co-marketing dealmakers

Chapter 7 - Co-promotion and co-marketing agreement contracts directory 2014- 2021

Appendices

TABLE OF FIGURES

(주)글로벌인포메이션 02-2025-2992 koreainfo@gii.co.jp
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기